Luminal breast cancer (HR+), the most prevalent subtype (about two-thirds) (77), derives limited benefit from NAC (78), showing substantially lower pCR rates than HER2-enriched and triple-negative breast cancers (79). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.